Due to the severe side-effects (cardiovascular events and benign prostatic hyperplasia) resulted from long-term or large dose of androgen administration, androgen supplementation is strictly limited [2], and selective androgen receptor modulators (SARMs) especially the non-steroidal tissue-specific SARMs were used currently to activate AR in specific tissue. The gene discussed is AR; the disease is benign prostatic hyperplasia.